E Tech Group Announces Brand Name Change of Recently Acquired System Integrator, E-Volve Systems

E Tech Group

E Tech Group, a leader in providing high-quality automation, control, and engineering services for industrial clients and Gold Certified Rockwell Automation Partner, today announced that the brand formerly known as E-Volve Systems has now been renamed as E Tech Group.

E-Volve Systems will operate under the name E Tech Group

Effective immediately, the brand formerly known as E-Volve Systems will operate under the name E Tech Group, unifying the two entities under one market-leading brand. The transition to the new name will be seamless for clients and partners. All existing commitments remain in place, ensuring continuity and stability.

“We’ve gained the ability to market and deliver large scale projects that may not have been available to us prior to the acquisition due to our size,” said Kevin Stout, previous E-Volve Systems founder and president and current vice president at E Tech Group. “We’ve also gained a tremendous network of team members whose skillsets seem to be limitless.”

E Tech Group’s acquisition of E-Volve Systems was finalized on February 23, 2023. This strategic move allowed E Tech Group to significantly expand its range of services, thereby enhancing the overall value offered to its clients. The acquisition was a step towards integrating complementary strengths, consolidating market presence, and fostering innovation in service delivery.

Matt Wise, Chief Executive Officer of E Tech Group Comments

“The name change at this time is a formality as E-Volve Systems has been a part of the E Tech Group since late February 2023,” said Matt Wise, Chief Executive Officer of E Tech Group. “Their contributions have positioned E Tech Group to elevate its service offerings and reach with the added benefit of resources located throughout North America as well as a broader suite of services, allowing us to automate every facet of a facility, from process and discrete automation through cybersecurity and data intelligence services, leveraging a team of over 600 automation specialists.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”